SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported) October 25, 2004 ---------------- Progenics Pharmaceuticals, Inc. ------------------------------- (Exact name of registrant as specified in its charter) Delaware 000-23143 13-3379479 -------- --------- ---------- (State or other jurisdiction (Commission (IRS Employer of incorporation) File Number) Identification No.) 777 Old Saw Mill River Road, Tarrytown, New York 10591 ------------------------------------------------------ (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code (914) 789-2800 -------------- -------------------------------------------------------------- (Former name or former address, if changed since last report.) Section 8 - Other Events Item 8.01 Other Events Announcement that the Board of Directors has elected current directors Kurt W. Briner and Paul F. Jacobson each to serve as non-executive Co-Chairman of the Board. They assume the chairmanship from Progenics' founder, Paul J. Maddon, M.D., Ph.D., who maintains his positions as Chief Executive Officer, Chief Science Officer, and a Company director. Section 9 - Financial Statements and Exhibits Item 9.01 Financial Statement and Exhibits (c) the following exhibits are filed with this report Exhibit Number Description 99.1 Press release dated October 25, 2004 ---------------- SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. PROGENICS PHARMACEUTICALS, INC. By: /s/ ROBERT A. MCKINNEY ----------------------------------------- Robert A. McKinney Vice President, Finance & Operations Date: October 25, 2004